

**MINUTES – Approved** 

# Public Meeting of the Board of Healthcare Improvement Scotland

Date: 7 December 2022 Time: 10.00 Venue: Hybrid - Conference Room, Delta House, Glasgow / MS Teams

## Present

Carole Wilkinson, Chair Abhishek Agarwal, Non-executive Director Jackie Brock, Non-executive Director Keith Charters. Non-executive Director Suzanne Dawson, Non-executive Director/Chair of the Scottish Health Council John Gibson, Non-executive Director Gill Graham, Non-executive Director Nicola Hanssen, Non-executive Director Rhona Hotchkiss. Non-executive Director Judith Kilbee. Non-executive Director Evelyn McPhail, Non-executive Director Doug Moodie, Chair of the Care Inspectorate Robbie Pearson, Chief Executive Michelle Rogers, Non-executive Director Duncan Service, Non-executive Director Rob Tinlin, Non-executive Director

# In Attendance

Sybil Canavan, Director of Workforce Lynsey Cleland, Director of Quality Assurance Ruth Glassborow, Director of Improvement Ann Gow, Deputy Chief Executive/Director of Nursing, Midwifery and Allied Health Professions (NMAHP) Ben Hall, Head of Communications Lindsey McIntosh, Interim Director of Community Engagement Angela Moodie, Director of Finance, Planning and Governance Lynda Nicholson, Head of Corporate Development Safia Qureshi, Director of Evidence

# **Apologies**

Simon Watson, Medical Director

## **Board Support** Pauline Symaniak, Governance Manager

## **Declaration of Interests**

Declaration(s) of interests raised are recorded in the details of the minute.

## **Registerable Interests**

All Board members and senior staff are required to review regularly and advise of any updates to their registerable interests within one month of the change taking place. The register is available on the Healthcare Improvement Scotland website.

1.	OPENING BUSINESS	ACTION
1.1	Chair's welcome and apologies	
	The Chair opened the public meeting of the Board by extending a warm	
	welcome to all in attendance including those in the public gallery.	
	Apologies were noted as above.	
1.2	Register of Interests	
	The Chair asked the Board to note the importance of the accuracy of the Register of Interests and that changes for the Register must be provided to the Planning and Governance Office within one month of them occurring. Any interests should be declared that may arise during the course of the meeting.	
	The Register was approved for publication on the website.	
1.3	Minutes of the Public Board meeting held on 28 September 2022	
	The minutes of the meeting held on 28 September 2022 were accepted as an accurate record.	
1.4	Action points from the Public Board meeting on 28 September 2022	
	The action point register was reviewed in respect of the one item related to the Covid-19 Inquiry. Thanks were extended to Lynda Nicholson for her ongoing work in this area. There were no matters arising.	
1.5	Chair's Report	
	The Board received a report from the Chair updating them on recent strategic developments, governance matters and stakeholder engagement. The Chair highlighted that she will shortly have a meeting with the Chair of the Independent Review of Inspection, Scrutiny and Regulation.	
	In response to a question from the Board about topics covered at the meeting with Scottish Government sponsors on 1 December 2022, the Chair advised that the items discussed were finances and the demands on small Boards to complete large returns of information. The sponsor team agreed to take the second point away for consideration.	
	The Board noted the report and were assured by the activities set out.	
1.6	Executive Report	
	The Board received a report from the Chief Executive and the Executive Team providing information on headline issues and key operational developments.	
	<ul> <li>The Chief Executive highlighted the following points:</li> <li>a) Throughout the report the level of stretch to respond to demands is obvious alongside the pressure to reach a balanced budget. This is a challenge for the Executive Team and the wider organisation.</li> <li>b) The winner of the Margaret McAlees award was announced as Jane Davies for her work in equalities and improving outcomes for marginalised people. As Jane sadly passed away earlier this year,</li> </ul>	

c)	the presentation of the award will be made to members of her family at the end of the Board meeting today. Regarding the National Care Service, HIS gave evidence to Parliament on regulatory and scrutiny aspects. Clarity of the Bill is awaited.	
d)	The pressure on the Scottish Medicines Consortium (SMC) is set out in the report and they are currently only able to assess three or four new medicines per month. Alongside this, there is a backlog. A bid was submitted to Scottish Government for £1.8m of additional funding but we have not received an outcome as yet in relation to this bid. The pressures and plans to respond to them will be discussed at a meeting with the Scottish Government's Chief Pharmaceutical Officer the following day.	
publica	irector of Quality Assurance highlighted two recent high profile ations: The report into independent assurance of infection prevention and control (IPC) in the Queen Elizabeth University Hospital. The report received some media attention. The assessment of IPC was generally good and there have been improvements in culture since the previous site visit. The safe delivery of care inspection report for Forth Valley Royal Hospital. The hospital has now been escalated to Stage 4 of NHS Scotland's National Performance Framework by Scottish Government.	
g)	bonse to questions from the Board, the Chief Executive and tive Team provided the following additional information: Regarding the escalation of two independent healthcare providers, this does not happen very often as HIS seeks to work with providers to secure improvements. However there was an element of safety risk and therefore swift action was required. HIS shares regular communications with providers about enforcement action and also uses networks to issue information. Regarding the pressures within SMC, the SMC's new Chief Pharmaceutical Adviser joined two weeks previously. The SMC	Director of Evidence
	risks will be reviewed to ensure they are accurately captured and scored. Other work to address the pressures includes assigning job roles in the most efficient way and using the Innovative Licensing and Access Pathway (ILAP). However, there has been a hiatus in this due to the Medicines and Healthcare products Regulatory Agency reviewing its processes but it is hoped it will bring gains in the longer term. Early communications are being used to share the position with industry as openness and transparency are important when communicating with the pharmaceutical companies. A prioritisation process is in place such that the medicines with the biggest potential impact are assessed first. There are issues with using a process of interim acceptance because follow-up data is often difficult to find. There	
i)	are similar delays in England. In terms of joint working, links have been strengthened with the National Institute for Health and Care Excellence and with Health Technology Wales. We are now looking to strengthen these further with work to assess new medicines. ILAP is also a four nation collaboration. Regarding the business case for funding for Excellence in Care and the Healthcare Staffing Programme (HSP), it was agreed that	

		I
	when the HSP was enacted, the funding would become	
	baselined. Negotiations are ongoing and it is a risk but there is	
	more confidence about receiving this than other allocations given	
	the legislative underpinnings of this work.	
	The Board examined in detail the report from the Executive Team and	
	the additional information provided above, and were assured by the	
	information reported.	
2.	SETTING THE DIRECTION	
<b>Z</b> .		
2.1	Transfer to HIS of the Right Decision Service	
	The Director of Evidence provided a paper that proposed transferring the	
	Right Decision Service (RDS) to the Evidence Directorate in HIS. She	
	highlighted the following key points about the proposed transfer:	
	a) RDS is a web based decision platform that hosts decision support	
	tools and guidelines comprising two categories – national	
	guidance as well as local tools and guidance.	
	b) The platform was developed by the Digital Health and Care	
	Innovation Centre and is now quite extensive with growing	
	content. The technical basis of the system is well established.	
	c) Scottish Government have approved funding of £2.3m until March	
	2025 to further develop RDS on condition it is moved to sit within	
	a health Board.	
	d) There is work needed to improve the platform but it aligns to our	
	strategic direction and HIS can add value to the system. It creates	
	many opportunities to increase our digital ambition and provide	
	enhanced access to our guidance as well as being a once for	
	Scotland digital health site.	
	e) The proposal has been scrutinised in detail by the Executive	
	Team and the Quality and Performance Committee. Questions	
	raised were covered as follows:	
	I. There is an exit strategy because there is no ongoing	
	financial or workforce commitment beyond March 2025	
	when funding ends. At that point additional funding will be	
	sought or the programme brought to an end. The HIS	
	finance and HR teams reviewed the proposals and did not	
	identify any risks.	
	II. The platform itself is not a risk because it uses well	
	established technology and HIS does not need to have	
	specific technical skills to support it.	
	III. Local content is currently approved by submitting Boards if	
	it is local content. There is an opportunity here for HIS to	
	improve and develop the governance supporting the	
	platform.	
	IV. The platform contains calculators that are considered to be	
	medical devices and standards related to this are about to	
	change. The highest regulatory burden sits with the	
	designated manufacturers, which is not HIS. We are	
	confident that they have well managed systems, of the	
	required standards, already in place.	
	required standards, aneady in place.	
	In response to questions from the Roard, the following additional	
	In response to questions from the Board, the following additional	
	information was provided:	
	f) The varied uses for the system are set out in the appendix and	
	include advice for high risk prescriptions in primary care in NHS	

() f () () () () () () () () () () () () ()	<ul> <li>Highland; wellbeing support checklists for health and social care settings such as a care home; NHS Greater Glasgow &amp; Clyde are using it for department specific practical guidance.</li> <li>g) We are not aware of any opposition to the system.</li> <li>h) There are income generation opportunities, for example leasing it to other countries, but these are not currently large and leasing could be complex. However, it is worth considering as the system develops.</li> <li>i) In terms of management time to implement the system, the direction of travel has already been to change how we present information and RDS supports that as well as helping us to do it more efficiently.</li> <li>j) Use of the site is already monitored with various stats and page visits information so that will allow HIS to demonstrate impact. It will be important to continue to work with NHS Education for Scotland (NES), for example, to ensure there is a link to postgraduate learning.</li> </ul> The Chair of the Quality and Performance Committee advised that the Committee have considered the transfer of RDS on three occasions and focused on several areas including clinical and care governance risks and regulatory aspects. As well as this, the Committee Chair held discussions with the Director of Evidence, the Medical Director and the Chief Executive. There are three areas to maintain oversight of during development: clinical and care governance, engagement with clinicians and NES, and the governance of processes that sit within the system. However, the Committee is content to recommend the proposal to the Board. Having considered the information set out in the report and provided above, and taking into account the recommendation from the Quality and Performance Committee, the Board approved the transfer of RDS to HIS.	
	· ·	
	Ways of Working Update	
	<ul> <li>The Director of Finance, Planning and Governance provided an update on the new ways of working following the end of the test of change period and highlighted the following points: <ul> <li>a) The paper presented aims to provide staff with guidance and was also considered by the Staff Governance Committee at their meeting the previous day.</li> <li>b) The work was taken forward by a small group comprised of Partnership Forum representation, HR, communications and the Employee Director. They examined the feedback from the test of change period.</li> <li>c) The overall conclusion was that the new ways of working had operated well and efficiently and therefore there was no reason to change going forward.</li> <li>d) The group also looked at staff contracts because every contract requires a base to be stipulated. Current policies were examined and Unison advice sought but it was agreed in partnership that there was no reason to change current contracts.</li> <li>e) The work also includes a focus on the role of the line manager for monitoring staff wellbeing and no change in travel costs are anticipated.</li> </ul> </li> </ul>	

bri	ommittee examined the report in detail and endorsed the proposal to ring the test of change period to an end while moving forward ways of orking as business as usual.	
	aving considered the paper and the information above, the Board had o questions and were content to approve the guidance for staff.	
3. AS	SSESSING RISK	
3.1 Ris	isk Management: strategic risks	
Th risl and pro deu rela	The Board received a report on the current status of risks on the strategic sk register and their management. The Director of Finance, Planning and Governance advised that the strategic risk register presented rovides the position at the end of November 2022. The risks have becreased from 12 to 11 due two previous risks being combined in relation to covid and external developments. There are no changes to things but controls and mitigations are under ongoing review.	
Ge alw we	response to questions from the Board about risk 759, related to eneral Data Protection Regulations, it was advised that this risk is ways present and would result in reputational damage if the regulations ere not adhered to. However, it is rated medium meaning that the itigations in place are enabling it to be managed to an acceptable level.	
Co	ne Chair of the Staff Governance Committee advised that the ommittee asked at the meeting the day before for the workforce risk to e updated to better reflect current circumstances.	
coi	ne Board considered the strategic risk register and, subject to the omments above, gained assurance that the risks presented were being fectively treated, tolerated or eliminated.	
4. HC	OLDING TO ACCOUNT – INCLUDING FINANCE AND RESOURCES	
4.1 Int	tegrated Planning	
Th set	<ul> <li>ne Director of Finance, Planning and Governance provided a paper etting out the position in relation to planning for 2023-24 and highlighted e following points: <ul> <li>a) The paper is presented for awareness and sets out an update on the progress of the integrated planning process for 2023/24.</li> <li>b) At this point it shows a decrease from 95 work programmes to 75. This is a 20% decrease and is indicative of the reduced funding available into next year.</li> <li>c) The budget is balanced at the moment but is not sustainable as a number of directorates are over budget, mostly due to pay costs. This means there are no funds for investment or contingency. Therefore directorate submissions will be reviewed.</li> <li>d) Pay costs are £400k over budget and therefore the headcount</li> </ul> </li> </ul>	

	the year.	
	<ul> <li>f) £1.5m of recurring savings are needed next year. This assumes a pay award of 5% next year and flat baseline funding.</li> <li>g) The proposals are draft but next steps have been agreed by the Executive Team and the plans will be ready for the Board to consider at the Board seminar in January 2023.</li> </ul>	
	<ul> <li>In response to questions from the Board, the following additional information was provided:</li> <li>h) There is a discrepancy in the workforce figures because the workforce report uses headcount while the budget uses WTE. The baseline WTE in 2023/24 is budgeted at 434 but when budget targets were set, an average WTE figure of 410 was calculated in order to be affordable next year. The total headcount currently is over 500. Consideration will be given to aligning these figures.</li> <li>i) The transfer to HIS of RDS does not remove the need for a new website as they offer different products but the two will be aligned.</li> <li>j) Two Additional Allocations for the ihub have not been confirmed and only verbal assurance has been given. Discussions are underway about which ihub allocations will be extended next year. Action will need to commence in January 2023 for staff on fixed term contracts for those projects that won't be funded next year. If those staff are redeployed, they are then not available to deliver the work if a decision is made by Scottish Government to proceed with funding. Scottish Government are aware but are also dealing with a high level of uncertainty.</li> <li>k) It is not possible to return an overspend position more than 1% at the end of the year and therefore the aim is to be in financial balance despite the challenges with Additional Allocations. The back to budget actions are challenging and create uncertainty and anxiety for staff. The One Team work aims to secure recurring savings for future years.</li> <li>l) The basis of maintaining motivation within staff during this difficult period is fairness, transparency, consistency and application of the Staff Governance standards. There will be a person centred, empathetic approach in communications during this time.</li> </ul>	Director FPG/ Director Workforce
	The Board examined the information provided and endorsed the first draft of the integrated plan for 2023/24 and next steps.	
4.2	Workforce Plan	
	<ul> <li>The Director of Workforce provided the draft Workforce Plan 2022-25 and took the meeting through a presentation which covered the following areas:</li> <li>a) The governance processes applied to the plan up to this point.</li> <li>b) The detailed aspects of the content of the plan as well as financial assumptions and their impact on headcount and WTE.</li> <li>c) The influence of the One Team programme.</li> <li>d) Reflections and recommendations from the Staff Governance Committee who had reviewed the plan the day before.</li> </ul>	
	The Chair of the Staff Governance Committee advised that the Committee discussed the plan in detail at their recent meetings and were content with the detail for this year while noting that it will need to remain fluid to reflect the current operating context.	

	<ul> <li>In response to questions from the Board, the following additional information was provided:</li> <li>e) The cross-directorate nature of the plan will be strengthened in the narrative. The cross-directorate redesign is being driven by the One Team but some parts are moving at a faster pace than others due to the financial situation.</li> <li>f) The new medical model mentioned refers to how clinical expertise is brought into and used within HIS. It will ensure that clinical leadership is deployed in an effective way across the whole organisation with a small cohort supporting the key delivery areas.</li> </ul>	
	The model mostly covers medical expertise as nursing, midwifery and allied health professional expertise is provided by staff employed within that directorate. Having considered the draft plan and the responses above, the Board were content to endorse it for publication.	
4.3	Organisational Performance Report	
4.3.1	<ul> <li>Quarter 2 Performance Report</li> <li>The Director of Finance, Planning and Governance provided a summary report of quarter 2 performance against the work programme and highlighted the following information from within the report: <ul> <li>a) The position set out is at the end of September 2022 and the Quality and Performance Committee received a more detailed report as at that position.</li> <li>b) Four key performance indicators are behind target: inspections, independent healthcare inspections, SMC and the financial overspend.</li> <li>c) In relation to the work programme, more projects are now delayed or repositioned and only 65% of projects are on track. This trajectory is expected to continue into quarter 3.</li> <li>d) The paper includes the key points from the discussion of performance by the Quality and Performance Committee which included the high proportion of Additional Allocations at risk in the ihub and the improvement support being provided to NHS Ayrshire and Arran.</li> </ul> </li> </ul>	
	<ul> <li>information was provided:</li> <li>e) The inspections backlog includes follow-up inspections but of the others, a risk based approach is taken so effort is focused on those where there are emerging concerns. The backlog arose due to the pandemic but new inspectors are now trained so the position should improve. It is difficult to predict a timeline for clearing the backlog due to new service registrations or other demands on resources.</li> <li>f) Regarding new commissions, more are being recorded that were previously declined but not reported. The Quality and Performance Committee received as part of their report the details of new commissions that were declined. This was due to the work being more appropriate for another organisation to deliver or due to the current financial constraints.</li> <li>The Board examined the performance report and gained assurance from the progress reported.</li> </ul>	

The Director of Finance, Diapping and Covernance provided a summary	
<ul> <li>The Director of Finance, Planning and Governance provided a summary report setting out the financial position as at the end of October 2022 and highlighted the following points: <ul> <li>a) The Audit and Risk Committee received a more detailed report covering the same period.</li> <li>b) The current position is a £300k overspend on the baseline which is equal to 1.5%. Pay costs are overspent by £800k but non-pay costs are underspent by £500k.</li> <li>c) Of Additional Allocations, £6.2m is confirmed or received leaving £2.5m not confirmed against which £1.3m has been spent and 33 WTEs assigned.</li> <li>d) A number of initiative are in place to reduce the overspend so a balanced budget is anticipated at year end.</li> </ul> </li> <li>The Board scrutinised the financial report and were content with the position reported.</li> </ul>	
Workforce Report	
<ul> <li>The Director of Workforce took the meeting through the workforce report and highlighted the following points: <ul> <li>a) The paper provided to the Board is a summary of the more detailed information that was provided to the Staff Governance Committee.</li> <li>b) The report provides a breakdown of WTEs and fixed term contracts, as well as detail on recruitment campaigns.</li> <li>c) The absence figure is less than the equivalent time last year and lower than the NHS Scotland target. Anxiety and depression remain the most common causes.</li> <li>d) The gender pay gap is now being reported as part of the equally safe activity.</li> </ul> </li> <li>In response to a question from the Board about the gender pay gap, it was advised that a standardised methodology is used to calculate it. The key outcome is reporting the information and making it available to the public.</li> <li>Having scrutinised the report, the Board were assured by the workforce information set out.</li> </ul>	
ENGAGING STAKEHOLDERS	
Improvement Work with NHS Lothian on Unscheduled Care	
<ul> <li>The following people joined the meeting for this item: Belinda Robertson, Head of Improvement Support, HIS; Jill Gillies, Programme Director Unscheduled Care, NHS Lothian; Denise Nasri, Senior Project Manager Unscheduled Care, NHS Lothian; Chris Connolly, General Manager, Royal Infirmary Edinburgh.</li> <li>Along with the Director of Improvement and the Head of Improvement Support, colleagues from NHS Lothian delivered a presentation about the HIS improvement support provided in unscheduled care. The presentation covered the following areas:</li> <li>a) How the ihub purpose supports the overall HIS purpose and a</li> </ul>	
	<ul> <li>highlighted the following points: <ul> <li>a) The Audit and Risk Committee received a more detailed report covering the same period.</li> <li>b) The current position is a £300k overspend on the baseline which is equal to 1.5%. Pay costs are overspent by £800k but non-pay costs are underspent by £500k.</li> <li>c) Of Additional Allocations, £6.2m is confirmed or received leaving £2.5m not confirmed against which £1.3m has been spent and 33 WTEs assigned.</li> <li>d) A number of initiative are in place to reduce the overspend so a balanced budget is anticipated at year end.</li> </ul> The Board scrutinised the financial report and were content with the position reported. Workforce Report The Director of Workforce took the meeting through the workforce report and highlighted the following points: <ul> <li>a) The paper provided to the Board is a summary of the more detailed information that was provided to the Staff Governance Committee.</li> <li>b) The report provides a breakdown of WTEs and fixed term contracts, as well as detail on recruitment campaigns.</li> <li>c) The absence figure is less than the equivalent time last year and lower than the NHS Scotland target. Anxiety and depression remain the most common causes.</li> <li>d) The gender pay gap is now being reported as part of the equally safe activity.</li> </ul> </li> <li>In response to a question from the Board about the gender pay gap, it was advised that a standardised methodology is used to calculate it. The key outcome is reporting the information and making it available to the public.</li> </ul> <li><b>ENGAGING STAKEHOLDERS</b> Improvement Work with NHS Lothian on Unscheduled Care. The following people joined the meeting for this item: Belinda Robertson, Head of Improvement Support, HIS; Jill Gillies, Programme Director Unscheduled Care, NHS Lothian; Chris Connolly, General Manager, Royal Infirmary Edinburgh. Along with the Director of Improvement and the Head of Improvement Support, colleagues from NHS Lothian d</li>

6.2
6.1
6.

6.3	Audit and Risk Committee: key points from the meeting held on 23	
	November 2022 and approved minutes from the meeting on 7 September 2022	
	The Board noted the key points and minutes.	
6.4	Quality and Performance Committee: key points from the meeting on 2 November 2022 and approved minutes from the meeting on 17 August 2022	
	The Board noted the key points and minutes.	
6.5	Scottish Health Council Committee: key points from the meeting on 17 November 2022 and approved minutes from the meeting on 15 September 2022	
	The Board noted the key points and minutes.	
6.6	Staff Governance Committee: the next meeting will be held on 6 December 2022	
	The Chair of the Committee advised that the meeting was held the day before and the key points from this were the review of the voluntary redundancy scheme, equality networks update and progress with One Team.	
	The Board noted the verbal update.	
6.7	Succession Planning Committee: next meeting will be held on 19 January 2023	
	It was noted that the Committee had not held a meeting.	
7.	ANY OTHER BUSINESS	
	The Chair drew the meeting's attention to the fact that this was the last Board meeting attended by Board Member Rhona Hotchkiss as her term of appointment ends on 28 February 2023. The Chair extended thanks to Rhona for her contribution to the Board over the four years of her appointment and in particular for her leadership of the Executive Remuneration Committee.	
8.	DATE OF NEXT MEETING	
8.1	The next meeting will be held on 29 March 2023.	
	Name of person presiding: Carole Wilkinson	
	Signature of person presiding:	
	Caule Wilkins,	
	Date: 29/3/23	